Literature DB >> 8575859

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines.

D C Zhou1, S Ramond, F Viguie, A M Faussat, R Zittoun, J P Marie.   

Abstract

To investigate the mechanism of resistance to an antineoplastic natural product homoharringtonine (HHT) in leukemic cells, we have established 5 sub-lines of human myeloid leukemia K562 cells, designated as K-H30, K-H100, K-H200, K-H300 and K-H400, which showed progressive resistance to different concentrations of HHT. These sub-lines were cross-resistant to daunorubicin, vincristine, etoposide and mitoxantrone, but not to melphalan. Immunofluorescence with monoclonal anti-Pgp antibody MRK16 and Northern-blot analysis demonstrated that resistance to HHT is related to the sequential emergence of MRP- and MDR1-gene over-expression. In the low-level-resistant K-H30 sub-line, the MDR1 gene was not over-expressed, but the MRP gene was over-expressed 2.1-fold. In the intermediate-level-resistant K-H100 and K-H200 sublines, both the MRP and the MDR1 genes were over-expressed. However, in the high-level-resistant K-H300 and K-H400 sublines, MDR1-gene over-expression predominated (20- and 21-fold respectively). On the other hand, GST pi-gene expression was decreased in all 5 sub-lines. Southern-blot analysis revealed no MRP-gene amplification in any of the 5 sub-lines, whereas the MDR1 gene was amplified in the high-level-resistant K-H300 and K-H400 sub-lines. The most interesting observation is a homogeneously staining region (HSR) found in chromosome 2 of the K-H300 and K-H400 sub-lines. Chromosome painting and in situ hybridization demonstrated that this HSR was translocated from chromosome 7 and consisted of the amplified MDR1 gene, suggesting that there is a relationship between MDR1-gene, translocation and MDR1-gene amplification.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8575859     DOI: 10.1002/(SICI)1097-0215(19960126)65:3<365::AID-IJC15>3.0.CO;2-9

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.

Authors:  Nathalia Daflon-Yunes; Flavio Eduardo Pinto-Silva; Raphael Silveira Vidal; Bruna Fortunato Novis; Tandressa Berguetti; Raphael Rodrigues Soares Lopes; Carla Polycarpo; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2013-07-23       Impact factor: 3.396

Review 2.  Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1).

Authors:  Eva Bakos; László Homolya
Journal:  Pflugers Arch       Date:  2006-12-23       Impact factor: 3.657

3.  The Metabolic Signature of AML Cells Treated With Homoharringtonine.

Authors:  Yulong Zhang; Na Li; Zhiguang Chang; Huabin Wang; Hanzhong Pei; Dengyang Zhang; Qi Zhang; Junbin Huang; Yao Guo; Yuming Zhao; Yihang Pan; Chun Chen; Yun Chen
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

4.  P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.

Authors:  Ruoping Tang; Simy Cohen; Jean-Yves Perrot; Anne-Marie Faussat; Claudia Zuany-Amorim; Zora Marjanovic; Hamid Morjani; Fanny Fava; Elise Corre; Ollivier Legrand; Jean-Pierre Marie
Journal:  BMC Cancer       Date:  2009-06-23       Impact factor: 4.430

5.  Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).

Authors:  Ruoping Tang; Anne-Marie Faussat; Jean-Yves Perrot; Zora Marjanovic; Simy Cohen; Thomas Storme; Hamid Morjani; Ollivier Legrand; Jean-Pierre Marie
Journal:  BMC Cancer       Date:  2008-02-13       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.